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Abstract
Methotrexate (MTX) is an established therapy for patients with steroid dependent Crohn’s disease 
(CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug 
antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in 
patients with ulcerative colitis (UC), however newer data at least partially contradict this 
assumption. The following review will discuss recent data for the use of MTX in CD, UC and in 
combination with anti-TNF agents.
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Introduction
In 1989 Kozarek et al. were the first to report a beneficial effect of intramuscular MTX 
therapy in 21 patients with refractory CD or UC.1 It took an additional 6 years to confirm the 
clinical efficacy of MTX as induction regimen and yet another 13 years as maintenance 
therapy in patients with CD. Two landmark trials of the North American Crohn’s Study 
Group Investigators published in 1995 and 2000 established that 25 mg MTX given 
intramuscularly once weekly for induction and 15 mg MTX given intramuscularly once 
weekly for maintenance was more effective than placebo in improving clinical symptoms 
and reducing requirements for prednisone.2, 3 Still in the last 20 years MTX has rarely been 
used for the treatment of CD despite robust clinical evidence as illustrated by low 
prescription rates in large insurer databases.4-7 This is astonishing considering that MTX is a 
generic medication and one of the very few reasonably priced drugs with a proven clinical 
value in the treatment of steroid dependent CD. Possible reasons for the lack of success of 
incorporating MTX in the routine CD treatment algorithm might be the need for 
subcutaneous (sc) or intramuscular injections, the relative high incidence of nausea (around 
20%) if the patient is not treated with concurrent anti-nausea medications and the lack of 
additional assuring prospective studies in CD. However, more recently, MTX therapy is 
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becoming more in vogue in pediatric patients and is also investigated as a potential 
therapeutic approach in patients with UC.8-10
MTX therapy in pediatric and adult CD patients –new data
Since the first reports of an increased rate of hepato-splenic lymphoma (HDSTCL) in the 
setting of a combination therapy of a thiopurine with an anti-TNF agent in young males in 
2006, many pediatric centers have reduced the utilization of azathioprine (AZA) or 6-
mercaptopurine (6-MP) in pediatric patients.11, 12 According to a recent multi-center study, 
since 2006 a significant trend occurred towards the preferred use of MTX as first line 
immunomodulator (Figure 1).12
MTX monotherapy in pediatric CD patients has been shown to be successful in inducing 
steroid free remission and subsequently maintaining this remission in approximately 65% of 
the patients over the next 5 years.12, 13 Consequently it is highly likely that a considerable 
number of pediatric patients will transition to adult providers in the next years while being in 
remission on long term MTX therapy. In this scenario questions of long-term toxicity, 
specifically liver toxicity are likely to arise. Currently liver biopsies are only recommended 
in the setting of reproducible elevations of liver function tests, however, liver fibrosis or 
cirrhosis may also develop in the absence of abnormal liver values.10, 14 Thus a non-invasive 
method to monitor patients on long term MTX therapy would be desirable. Possibilities to 
monitor for liver toxicity in a non-invasive manner might be the use of transient elastography 
(TE; Fibroscan).15 However, currently no longitudinal studies evaluating this technology are 
available.10
Whereas the usefulness of MTX in adults in the first year has been analyzed in several 
studies, the availability continuous efficacy data beyond one year duration of therapy have 
been scarce.4 Hausmann et al performed a meta-analysis of 4 studies, including 267 CD 
patients with long-term follow up.16-20 In this analysis it becomes apparent that the 
cumulative probability to maintain remission on MTX monotherapy decreases by approx. 
30% over a 3 year time period (Figure 2), which seems contradictory to the above reported 
results in pediatric patients. A similar decrease of slightly more than 40% of sustained 
clinical benefit from 63% to 47% and 20% in year 1,2 and 5, respectively, after therapy 
initiation is reported in a multi-center analysis from the Netherlands.21 Even higher loss of 
response rates are described in a smaller study from a single center in England with a 
cessation of clinical benefit in 70% of the patients over a 3 year time period. 22 Multiple 
factors might influence the long term effectiveness of MTX in CD including medication 
compliance, lower and ineffective maintenance doses of MTX or as yet undefined escape 
mechanisms of the immune system, which lead to re-occurrence of intestinal inflammation 
despite ongoing immunosuppressive therapy.
New data of MTX and anti-TNF combination therapy
AZA/6-MP and MTX appear to be equally effective in suppressing antibody formation and 
preserving higher IFX trough levels.23 Subsequently the Study of Biologic and 
Immunomodulator Naive Patients in CD (SONIC) study revealed a greater clinical 
effectiveness of a combination approach of infliximab (IFX) and AZA compared to IFX 
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alone.24 One major factor for the increased efficiency of a combination approach is thought 
to be a lower likelihood of anti-IFX antibody formation and higher IFX trough levels. 
However, the currently available data of a clinical advantage of combination therapy appear 
not to be as convincing for other anti-TNF agents than IFX. MTX and anti-TNF 
combination therapy seems to prolong the long-term efficacy of all FDA approved anti-TNF 
agents in patients with rheumatoid arthritis.25 Yet currently, there is a lack of any prospective 
or large retrospective analyses in patients with IBD describing an increase of the short or 
long term efficacy and durability of a combination therapy of AZA/6-MP or MTX with one 
of the humanized anti-TNF antibodies adalimumab, certolizumab and golimumab.26 
Furthermore, the results of recently published study “The Combination Of Maintenance 
Methotrexate-Infliximab Trial (COMMIT) did not help to further elucidate the important 
question of a mono vs a combination approach in the setting of biological therapy.27 
COMMIT revealed that the addition of MTX to IFX lead to a significant suppression of 
antibody formation to IFX and higher serum IFX trough levels compared to IFX 
monotherapy. In contrast to SONIC, these serologic results did not correlate with an 
improvement in clinical outcome during the 50 weeks duration of the COMMIT trial. The 
reasons for the differences between COMMIT and SONIC can only be speculated upon, but 
several factors, which might have influenced the divergent outcomes in both trials have been 
suggested.28 These include different disease duration before inclusion in the trial in SONIC 
vs COMMIT (2.2 years vs 9 years), different inclusion criteria in regard to previous 
exposure to immunosuppressive medication and concurrent steroid therapy and “dual” 
therapy in SONIC (IFX + AZA) vs “triple” therapy in COMMIT (initial Steroid taper + 
single steroid application before each IFX infusion). Also, in contrast to the SONIC findings 
a recent study investigating the benefit of continuing AZA or 6-MP when starting anti-TNF 
agents (IFX or adalimumab) in the setting of step up therapy suggested a higher risk of 
opportunistic infections but no clinical benefit of a combination therapy.29 Data from a large 
pediatric registry recently revealed that in boys the overall durability of IFX therapy with 
concomitant MTX for ≥ 6 months after starting IFX was significantly better than with 
concomitant thiopurines. 30 At present no firm conclusion with regard to the question 
“which is the better combination therapy with IFX MTX or AZA/6-MP?” can be drawn.31 
Perhaps a recently funded pragmatic trial, which aims to compare the effectiveness of anti-
TNF alone or in combination with oral MTX (http://www.pcori.org/research-results/2015/
anti-tnf-monotherapy-versus-combination-therapy-low-dose-methotrexate) can help to 
further clarify the role of MTX in its role as anti-TNF adjunctive therapy. Additionally, the 
role of AZA/6-MP or MTX in combination with the other approved anti-TNF agents 
adalimumab, certolizumab and golimumab needs further exploration in clinical studies. 
Moreover, there remain open questions as to the dose and modality of MTX therapy: Do 
lower doses (e.g. 15 mg) have the same clinical efficacy as the higher dose of MTX in 
combination therapy? In maintaining remission in patients with CD 15 mg MTX sc seems to 
be inferior to 25 mg, but in combination therapy this might be different. Do the application 
modalities have an influence on efficacy and durability of combination therapy (sc vs oral)? 
MTX monotherapy is more effective if applied sc then orally, but again this might not have 
an impact in the setting of combination with anti-TNF.32-34 A recent retrospective chart 
review at a tertiary care center in the US addressed both questions.35 The study included 88 
IBD patients (74% CD, 22% UC, 4% indeterminate colitis) on anti-TNF therapy (49% on 
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adalimumab, 40% n IFX and 11 % on certolizumab), who were also treated with 
concomitant MTX therapy. The results revealed that patients on MTX doses of >12.5mg/
week had a higher likelihood to remain in clinical remission than those on lower doses and 
there was also a trend toward higher efficacy of parenteral vs oral MTX application. The 
results of the study are highly interesting but the overall number of included patients is small 
especially given the multiple analyses (3 different underlying disease conditions – CD, UC, 
indeterminate colitis; 3 different anti-TNF regimen, different MTX dose and application 
regimen). Clearly more research in this direction is needed. However the fact that doses of 
12.5 mg MTX/week might be too low to have any significant clinical efficacy is supported 
by yet another retrospective analysis of the durability of IFX therapy.36 In this single center 
analysis including pediatric patients, MTX doses <10 mg/ week were ineffective, since no 
difference in outcome was observed between children on IFX/MTX combination therapy 
compared to IFX monotherapy.
MTX in UC – is it therapeutically effective?
A multi-center study directed by Oren et al. investigated the efficacy of oral methotrexate at 
a dose of 12.5 mg orally/week compared to placebo in 67 patients with at least moderately 
active UC in the early 1990’s.37 The treatment duration was 9 months; 5-aminosalicylates 
(5-ASA) and steroids were allowed to be continued during the study at the discretion of the 
treating physician and the primary outcome measures were the proportion of patients 
entering first remission, time to reach that remission and maintenance of remission. There 
were no significant differences among the groups with regard to the primary outcomes, 
monthly steroid use, clinical Mayo scores or mucosal healing. Despite the positive results of 
3 other very small prospective studies, which also had significant qualitative weaknesses, the 
results from Oren et al. led to the conclusion that MTX is ineffective in the therapy of 
UC.9, 38 However, data from the recently presented METEOR (Comparison of Methotrexate 
vs Placebo in Corticosteroid-dependent Ulcerative Colitis) trial suggest a significant clinical 
efficacy in inducing steroid free remission.39 The aim of this trial was the investigation of sc 
applied MTX 25 mg/week as an induction regimen over 16 weeks. MTX was superior to 
placebo (42.0% vs 23.5%; p<0.04), when the investigators just analyzed the clinical efficacy 
excluding the sigmoidoscopy results (Figure 3). However the primary endpoint was a 
combined endpoint of the clinical and endoscopic Mayo score with a total score ≤2 and no 
item > 1, complete steroid withdrawal with a forced steroid tapering regimen and no need 
for other immunosuppressants, anti TNF or colectomy at week 16. With the addition of the 
endoscopy results the study missed the primary endpoint (Figure 3). Interestingly absence of 
rectal bleeding and normalization of stool frequency, both outcomes that are normally 
considered a surrogate marker of mucosal healing were significantly better in patients on 
MTX than those on placebo (Figure 4).40-42 Overall the study was most likely underpowered 
since the investigators had assumed that MTX would have a 45% probability of steroid-free 
remission, which is better than any currently available drugs for the treatment of UC. Other 
limitations of the METEOR design comprise the inclusion of patients with clinical and/or 
endoscopic inactive disease (but being steroid dependent) and the absence of central reading 
of the endoscopy scores. To put the METEOR results into perspective, the randomized 
prospective study compared AZA with IFX monotherapy and IFX/ AZA combination 
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therapy (SUCCESS trial) had a similar endpoint as METEOR and demonstrated steroid free 
remission for 24%, 22% and 40% of the patients, respectively.43 Of note the SUCCESS 
study population significantly differed from that of METEOR since only anti-TNF and AZA 
naïve patients or patients who had stopped AZA at least for 3 months before the study were 
included.
Currently a second study, which is sponsored by the National Institute of Health and 
performed by the Crohn’s and Colitis Foundation of America - Clinical Research Alliance 
(CCFA-CRA) is analyzing the efficacy of MTX in maintaining steroid free remission and is 
currently ongoing (“Randomized, double blind, prospective trial investigating the efficacy of 
Methotrexate in induction and maintenance of steroid free remission in ulcerative colitis 
(MEthotrexate Response In Treatment of UC - MERIT-UC); clinicaltrials.gov, 
NCT01393405). This study follows a withdrawal design similar to the landmark CD MTX 
maintenance study by Feagan et al.2 Patients who had failed at least one previous UC 
therapy (5-ASA, AZA/6-MP, anti-TNF or vedolizumab and/or are steroid dependent) are 
treated with open label MTX 25 mg sc/week with a concomitant steroid taper (Figure 5). 
The steroid taper has to be finished at week 12. If the patients are responding or are in 
remission at week 16 they are randomized to placebo or continuation of MTX therapy for 
another 32 weeks. Interims results are available for the first 96 patients who have completed 
the 16 weeks. 30% of the patients on open label MTX were in clinical remission defined by 
a clinical Mayo score ≤ 2 and 50% of all patients started on MTX were in clinical response 
defined as decrease in the Clinical Mayo score of ≥ 2 points and at least a 25% decrease 
from baseline Mayo score. The MERIT-UC trial is still ongoing and the final results of the 
placebo-controlled maintenance phase are expected for 2017.
Summary
MTX is becoming the preferred immunosuppressive agent in the therapy of pediatric CD 
either as mono or in combination therapy with biologics. The long-term efficacy in pediatric 
and adult patients appears to be comparable to AZA/6-MP therapy. In combination therapy 
with anti-TNF agents MTX has similar ability as AZA/6-MP to suppress IFX antibody 
formation and to increase the IFX trough level. Current evidence suggests that MTX should 
be administered at least at a dose ≥12.5 mg weekly to improve the efficacy of anti-TNF 
therapy, however there is still some debate about the optimal dose and the mode of 
application. The merits of MTX in inducing and maintaining steroid free remission in 
patients with active UC are still unresolved. The recently published results of the METEOR 
study missed the primary combined endpoint of steroid-free clinical and endoscopic 
remission. However a significant clinical effect of MTX compared to placebo, which was 
not matched by a significant improvement of mucosal inflammation suggest that the study 
was most likely underpowered. Thus METEOR ultimately failed to prove or refute a 
therapeutic effectiveness of MTX in UC. Hopefully the results of MERIT-UC are able to 
finally resolve the ongoing debate on the efficacy of MTX in patients with active UC.
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Figure 1. 
Trends of MTX use by year. Shown is the fraction of MTX as first choice immunomodulator 
a prospective pediatric inception cohort study in 2002 and by 2010. There was no gender 
difference in this trend.12
Herfarth Page 9
Dig Dis. Author manuscript; available in PMC 2017 March 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Cumulative probability to maintain remission on MTX in CD over 3 years.16
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Figure 3. 
METEOR results at week 16: Steroid free clinical and endoscopic remission and steroid free 
clinical remission only.39
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Figure 4. 
METEOR endoscopic and clinical endpoints at week 16: endoscopic healing defined as 
Mayo endoscopic subscore = 0 or 1 and patient reported outcomes of absence of rectal 
bleeding and normalization of bowel frequency.39
Herfarth Page 12
Dig Dis. Author manuscript; available in PMC 2017 March 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
Trial design of the MERIT-UC study with open label Induction Period and Placebo 
controlled Maintenance Period after randomization at week 16.
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